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Abstract
Many reviews on the CD1d/NKT cell axis focus on the ability of CD1d-restricted NKT cells to 
serve as effector cells in a variety of disorders, be they infectious diseases, cancer or 
autoimmunity. In contrast, here, we discuss the ways that viruses, bacteria and tumor cells can 
evade the CD1d/NKT cell axis. As a result, these disease states have a better chance to establish a 
foothold and potentially cause problems for the subsequent adaptive immune response, as the host 
tries to rid itself of infections or tumors.
Introduction
Classical antigen presentation in the cellular adaptive immune response occurs via the 
recognition of peptides presented by the major histocompatibility complex (MHC) class I or 
class II molecules, to conventional T lymphocytes [1,2]. In contrast, the MHC class I-like 
CD1d molecule presents lipids to natural killer T (NKT) cells [3]. Invariant NKT cells are 
defined as those CD1d-specific T cells that have an invariant T cell α chain rearrangement 
(Vα14-Jα18 in mouse; Vα24-Jα18 in humans). As part of the innate immune response, the 
CD1d/NKT cell axis has been shown to play various protective roles in anti-microbial and 
anti-tumor host defense [4–8]. However, several pathogens and tumor cells have various 
means to impair antigen (Ag) presentation by CD1d and/or NKT cell function.
CD1d acquires the lipid antigens it presents by an intracellular mechanism (Figure 1). CD1d 
molecules are synthesized in the endoplasmic reticulum and are loaded with a non-antigenic 
lipid [3,9,10]. Like other glycosylated proteins, they then traverse through the Golgi and are 
ultimately expressed on the cell surface [11]. However, these CD1d molecules are not loaded 
with a lipid that can stimulate NKT cells. Instead, thanks to a tyrosine-based endosomal 
targeting sequence [12], CD1d molecules re-enter the cells and traffic through late endocytic 
compartments, where the non-antigenic lipid is replaced by one that is. Upon re-expression 
on the cell surface, NKT cells can be activated [13]. In cancer, this process is metabolically 
“revved up” [14]. During certain virus infections, the intracellular location of CD1d is 
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altered [15]. We measure NKT cell activation in co-cultures (i.e., NKT cells with CD1d+ 
cells) by the release of cytokines (e.g., IL-2, IFN-γ, IL-4, GM-CSF, etc.) by the NKT cells.
This review will discuss the immune evasion strategies various pathogens and cancer cells 
use against the CD1d/NKT cell axis, which could provide potential future approaches to 
counter those measures. Figure 2 shows the different players reported to be able to impair 
the CD1d/NKT cell axis; many of these mechanisms are multi-functional. We will break 
down the immune evasion strategies, by discussing the different diseases individually: 1. 
Viruses; 2. Bacteria; 3. Tumor cells.
Immune evasion by viruses
Viruses have the capacity to impact the CD1d/NKT cell axis at both the CD1d+ antigen 
presenting cell (APC) and NKT cell levels. In fact, the simple act of a virus infection results 
in the loss of a large percentage of NKT cells by activation-induced cell death [16,17]. 
Interestingly, the decrease in NKT cells appears to be IL-12-dependent, yet CD1d-
independent [17]; IL-12 itself can cause the apoptotic loss of NKT cells [18]. That being 
said, administration of the NKT cell activating and CD1d-presented, synthetic glycolipid α-
galactosylceramide (α-GalCer; ref. [19]) to mice infected with murine cytomegalovirus 
(MCMV) or lymphocytic choriomeningitis virus (LCMV), results in enhanced viral 
clearance [20,21].
On top of this effect, viruses can target APCs. An acute LCMV infection in vivo causes a 
reduction in CD1d expression on dendritic cells and macrophages [22]; this may be due, in 
part, to alterations in cellular metabolism, resulting in a “danger signal” used by the 
CD1d/NKT cell axis as part of the innate immune response [23]. Importantly, cytopathic 
viruses are able to impact the functional expression of CD1d in multiple ways. After a 
vaccinia virus (VV) or vesicular stomatitis virus (VSV) infection, CD1d molecules are 
segregated to one side of a cell; this is concomitant with alterations in cell signaling 
pathways [10,15,24,25]. The VV-encoded proteins, B1R and H5R, and VSV matrix protein, 
also contribute to impairing Ag presentation by CD1d post-infection [24,25]. Herpes 
simplex virus-1 (HSV-1) alters the recycling of human CD1d [26,27], likely by inducing the 
phosphorylation of residues in its cytoplasmic tail [28,29]. Moreover, two HSV-1 encoded 
proteins, VP22 and US3, have been reported to contribute to the impairment of CD1d-
mediated Ag presentation post-HSV-1 infection [30–32]. The inhibition of NKT cell 
activation by HSV-1 is APC/NKT cell contact-dependent [33]. An MCMV infection results 
in a substantial reduction in myeloid progenitor cells in the bone marrow and spleen, 
especially in NKT cell- and CD1d-deficient mice [34]; this could be prevented by the 
adoptive transfer of NKT cells into wildtype and NKT cell-deficient mice before infection 
[34].
A human immunodeficiency virus (HIV) infection can target both NKT cells and CD1d+ 
APCs. NKT cells are reduced following infection with HIV [35–38] or simian 
immunodeficiency virus (SIV) [39]; this NKT cell loss is reversed quickly upon highly 
active antiretroviral therapy (HAART) [40]. In APCs, HIV causes a reduction in CD1d 
expression by the formation of a CD1d/Nef complex [41,42]. In contrast, an HIV-1 infection 
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of dendritic cells can result in a TLR7-dependent upregulation of CD1d, triggering NKT cell 
recognition of those cells [43]. The herpesvirus KSHV also affects both CD1d expression 
and NKT cell numbers [44,45], whereas the human papillomavirus E5 protein inhibits 
calnexin-dependent trafficking of CD1d [46]. Taken together, the reports indicate that 
viruses have multiple mechanism(s) whereby they impair CD1d-mediated Ag presentation 
or directly affect NKT cells.
Bacterial Infections and CD1d
There has been a variety of work describing bacterial infections that can impact the 
CD1d/NKT cell axis. For the most part, CD1d-mediated Ag presentation to NKT cells helps, 
rather than hurts, a host’s anti-bacterial host defense. An example of this is the requirement 
for CD1d in anti-Borrelia responses [47] and the identification of diacylglycerols from 
Borrelia burgdorferi (causative agent of Lyme Disease) as an NKT cell-stimulating Ag [48]. 
As indicated above with certain virus infections, α-GalCer has also been shown to protect 
mice against a Mycobacterium tuberculosis infection [49].
In other animal models (e.g., CD1d- or Jα18-deficient mice), the growth of Pseudomonas 
aeruginosa, Streptococcus pneumoniae, Sphingomonas and Ehrlichia muris is exacerbated as 
compared to wildtype mice [50]. For Sphingomonas, this makes sense, as this bacterium 
contains α-glucoronosylceramide, which can be presented by CD1d and activate NKT cells 
[51–53]. Additionally, S. pneumoniae has diacylglycerol-containing glycolipids that can 
stimulate NKT cells [54]. Early following a Listeria monocytogenes infection, there is a 
transient reduction in IL-4-producing NKT cells [55,56]. In contrast, IFN-γ-producing NKT 
cells expand quickly post-infection [57]. Other bacteria, such as Chlamydia, have been 
shown to be less pathogenic in CD1d-deficient mice, in a mouse pneumonitis model [58]. 
Also in that report and in line with the results in CD1d KO mice, the activation of NKT cells 
enhanced Chlamydia growth in vivo. This seemed to be dependent upon the Chlamydia 
species, as the production of Th1 vs. Th2 cytokines upon NKT cell activation in vivo, 
resulted in reduced or enhanced bacterial growth, respectively [59]. Specifically, C. 
muridarum grew better when NKT cells were present, whereas a C. pneumoniae infection 
was controlled by NKT cells in vivo [60]. Others have reported that CD1d is degraded in C. 
trachomatis-infected human epithelial cells [61]. The anthrax lethal toxin impairs CD1d-
mediated Ag presentation by targeting the ERK1/2 mitogen-activated protein kinase [62]; a 
signaling pathway that we showed promotes Ag presentation by CD1d [15].
Thus, bacteria have the ability to affect the CD1d/NKT cell axis by either enhancing NKT 
cell-dependent responses against infection, or by directly altering the functional expression 
of CD1d on antigen presenting cells.
Immune evasion by cancer
Although the majority of work studying the CD1d/NKT cell axis has been in the innate anti-
cancer immune response [63], tumor cells have been notorious for evading the immune 
system. Thus, overall, how do we develop cancer if our immune system is apparently “OK”? 
One way in which cancer cells can prevent immune attack by antitumor effector T cells (e.g., 
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CD8+ CTL and NKT cells) is by simply downregulating β2microglobulin (β2m). As both 
MHC class I and CD1d molecules are associated with β2m, this allows a tumor to kill two 
birds with one stone and is a common means of immune evasion by melanoma and 
colorectal carcinoma, for example [64]. CD1d+ tumors have the capacity to evade 
recognition by NKT cells by shedding glycolipids, which presumably replace endogenous 
lipids bound to CD1d, and which cannot be recognized by NKT cells. These glycolipids 
include gangliogtriaosylceramide shed by the murine T cell lymphoma line, L5178Y-R [14], 
or the ganglioside GD3 by human ovarian cancer cells [65]. Cells that constitute the blood 
cancer multiple myeloma are CD1d+ [66]; however, as the disease progresses, the level of 
CD1d is decreased [67]. Additionally, MM patients have defects in NKT cell function in 
vivo; this is “reversible”, in that α-GalCer can activate these NKT cells ex vivo [66]. 
Moreover, advanced prostate cancer patients have a reduction in circulating NKT cells; those 
that do exist are defective in their ability to produce IFN-γ [68].
Immune responses to tumors are not generally polarized toward a single arm (e.g., only 
innate). Both the innate and adaptive immune responses will work together as a network 
with one arm regulating another and vice versa [69]. Overall, immune evasion mechanisms 
can impair one or more elements of the immunological network; alternatively, the tumors 
themselves can shed immunosuppressive (or CD1d blocking) glycolipds or reduce their own 
surface CD1d which reduces circulating NKT cells. Understanding those mechanisms will 
reveal potential targets for novel therapeutic paradigms using the CD1d/NKT cell axis.
Conclusions
In this review, we briefly discussed the ways in which a variety of viruses, bacteria and 
tumors can impair the CD1d/NKT cell axis. This can be by affecting the antigen presenting 
cells, by either down regulating CD1d itself or disrupting cell signaling pathways. 
Alternatively, impacts on NKT cell numbers and function can also prevent a significant anti-
microbial pathogen or anti-tumor immune response in a host. That being said, understanding 
the ways in which microbial pathogens and tumors can evade host defense, will provide 
insight into the identification of new targets one could use in novel treatment paradigms--in 
each of these disease states.
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• Viruses, bacteria and tumors can impair the CD1d/NKT cell axis
• CD1d can be downregulated or cell signaling pathways disrupted
• NKT cells can be directly infected and/or unable to recognize CD1d
• Immune evasion strategies might be used to develop new treatments 
paradigms
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Figure 1. Intracellular trafficking of CD1d molecules
CD1d molecules are synthesized in the endoplasmic reticulum (ER) and form a complex 
with β2m. It is within this compartment that CD1d is loaded with an endogenous glycolipid 
(GPI, PI, PC, etc.), facilitated by the microsomal triglyceride transfer protein (MTP). The 
complex then traverses through the Golgi complex and onto the cell surface. These lipid-
loaded molecules cannot be recognized by NKT cells. A Tyr-based endosomal targeting 
sequence (YXXΦ) causes the CD1d1-β2m-lipid complex to reenter the cell and traffic to 
intracellular vesicular compartments in the endocytic pathway. It is there that the first lipid 
can be replaced by the appropriate endogenous Ag(s) by a lipid transfer protein (LTP); it 
then returns to the cell surface, where it can now be recognized by NKT cells. EE, early 
endosomes; LE, late endosomes or early lysosomes; L, lysosomes. Modified from Roberts et 
al., Recycling CD1d1 molecules present endogenous antigens processed in an endocytic 
compartment to NKT cells, J. Immunol. 168:5409 – 5414, 2002. Copyright 2002. The 
American Association of Immunologists, Inc.
Brutkiewicz et al. Page 10





















Figure 2. Immune evasion targets
Viruses, bacteria and tumor cells have various means to evade the CD1d/NKT cell axis. 
Various viruses can target APCs and/or NKT cells, either directly or indirectly. Bacteria can 
infect APCs and impair the functional expression of CD1d. Lastly, can tumor cells can 
present aberrant lipids to NKT cells, effectively preventing their activation; alternatively, 
tumor cells can shed glycolipids from their membranes, binding to CD1d on normal APCs 
and preventing their recognition by NKT cells.
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